IPP Bureau
Eli Lilly to build new $6.5 billion orforglipron manufacturing facility in Texas
By IPP Bureau - September 24, 2025
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Lunit and Agilent collaborate to develop AI-powered diagnostic solutions for precision medicine
By IPP Bureau - September 24, 2025
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Poly Medicure acquires Italy’s Citieffe Group for Rs. 324 Cr
By IPP Bureau - September 24, 2025
Pharma Manufacturing & Automation Convention 2025 to be held on Oct. 8-9, 2025 in Hyderabad
By IPP Bureau - September 24, 2025
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy
By IPP Bureau - September 24, 2025
Agency initiates safety label change and notifies physicians of possible link
Teva unveils promising SOLARIS resultsfor Olanzapine LAI
By IPP Bureau - September 23, 2025
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Akums demonstrates clinical versatility of Lacosamide in epilepsy care
By IPP Bureau - September 23, 2025
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Roche’s subcutaneous lunsumio receives CHMP backing for R/R follicular lymphoma
By IPP Bureau - September 23, 2025
Moderna delivers Canada’s first locally manufactured mRNA vaccines
By IPP Bureau - September 23, 2025
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
By IPP Bureau - September 23, 2025
Importantly, the combination of giredestrant and everolimus was well tolerated
AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
By IPP Bureau - September 23, 2025
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Metropolis Healthcare acquires Ambika Pathology Laboratory
By IPP Bureau - September 22, 2025
Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada
By IPP Bureau - September 22, 2025
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Fermenta to sell environmental solutions business to its subsidiary
By IPP Bureau - September 21, 2025
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
